Overview

Also Known As:IFN-αβR-

Mice homozygous for this Ifnar1 knock-out mutation are more susceptible to viral infection, have an abnormal NK antitumor response, and reduced bone mass. This mutant mouse strain may be useful in studies of immunological responses to infection, and bone homeostasis. Mouse mutants involving this gene have been used in studies of Zika virus pathogenesis. Note: these mice carry the same allele as 'A129' mice, although on a congenic C57BL/6, not 129, genetic background.

Donating Investigator

Dr. Michel Aguet, EPFL, Ecole polytechnique fédérale de Lausanne

Genetic overview

Genetic Background	Generation
	N6+N1F8 (2018-11-30 00:00:00)

Ifnar1^tm1Agt

Allele Type	Gene Symbol	Gene Name
Targeted (Null/Knockout)	Ifnar1	interferon (alpha and beta) receptor 1

View Genetics

Research Applications

Immunology, Inflammation and Autoimmunity Research
Research Tools
Cancer Research
Cell Biology Research
Endocrine Deficiency Research

View All Research Applications

Details

Detailed Description

Mice that are homozygous for the targeted mutation are viable, fertile, and normal in size. No gene product (mRNA) is detected by Northern blot analysis of homozygous primary embryonic fibroblasts. Mice that are homozygous for this targeted allele lack type I IFN receptor function, exhibit enhanced osteoclastogenesis with decreased bone density, and impaired response to protozoan parasite (Leishmania) infection. NK cell mediated tumor regression does not occur in homozygotes in response to B16 melanoma tumor implant model. Mouse mutants involving this gene have been used in studies of Zika virus pathogenesis.

Development

A targeting vector containing neomycin resistance and herpes simplex virus thymidine kinase genes was used to disrupt exon 3. The construct was electroporated into 129S2/SvPas derived D3 embryonic stem (ES) cells. Correctly targeted ES cells were injected into recipient blastocysts. The mice were backcrossed to C57Bl/6 for at least 5 generations, as reported by the donating investigator.

Control Suggestions

000664 C57BL/6J

Additional Information

Considerations for Choosing Controls

Selected References

Muller U; Steinhoff U; Reis LF; Hemmi S; Pavlovic J; Zinkernagel RM; Aguet M. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264(5167):1918-21PubMed: 8009221 MGI: J:36115

View All References

Genetics

Ifnar1^tm1Agt

Allele Symbol: Ifnar1^tm1Agt

Allele Name	targeted mutation 1, Michel Aguet
Allele Type	Targeted (Null/Knockout)
Allele Synonym(s)	A 129; A^-; A129; IFN Alpha Ro/o; IFN type I receptor; IFN-alpha/betaR-; IFN-alpha/betaR/A129; IFN-alpha/betaR⁰; IFN-alphabetaR-; IFN-alphabeta-R KO; IFNAR(0); IFNAR^-; Ifnar1-; IFN-IR KO; IFN-IR^-; IFNR^-; IFNRA1,-.; IFNRI -; IFNRI KO
Gene Symbol and Name	Ifnar1, interferon (alpha and beta) receptor 1
Gene Synonym(s)
Strain of Origin	129S2/SvPas
Chromosome	16
Molecular Note	A neomycin cassette was inserted into exon 3 at a position corresponding to amino acid 88.
Mutations Made By	Dr. Michel Aguet, EPFL, Ecole polytechnique fédérale de Lausanne

Disease/Phenotype

Disease Terms

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Immunology, Inflammation and Autoimmunity Research
- Intracellular Signaling Molecules
- Immunodeficiency
  - NK Cell Deficiency
- CD Antigens, Antigen Receptors, and Histocompatibility Markers
  - genes regulating susceptibility to infectious disease and endotoxin
- Growth Factors/Receptors/Cytokines
Research Tools
- Infectious Disease
- Immunology, Inflammation and Autoimmunity Research
  - genes regulating susceptibility to infectious disease and endotoxin
  - NK Cell Deficiency
- Cancer Research
  - tumor immunology
Cancer Research
- Growth Factors/Receptors/Cytokines
Cell Biology Research
- Signal Transduction
Endocrine Deficiency Research
- Bone/Bone Marrow Defects

Mammalian Phenotype Terms by Genotype

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Ifnar1^tm1Agt/Ifnar1^tm1Agt
involves: 129S2/SvPas

cardiovascular system phenotype

corneal vascularization
- corneal injection of a plasmid encoding short hairpin RNA targeting the C terminus of the secreted form of Flt1 (pshRNA-sflt1) induces corneal vascularization within 3 days of injection in wild-type and mutant mice

liver hemorrhage
- MHV-infected mice develop an acute hemorrhagic liver disease with massive hepatocyte necrosis

hematopoietic system phenotype

abnormal immunoglobulin level
- levels of IgG1a, IgG2a and IgG2b neutralizing antibodies are reduced relative to controls after secondary infection with Ectromelia virus

abnormal NK cell physiology
- NK cells in vivo make much about a fifth less IFN-gamma in response to injections of the TLR9 agonist CpG
- there is 50% less actively proliferating NK cells in the spleen after MCMV infection compared to controls

impaired natural killer cell mediated cytotoxicity
- NK cells from MCMV-infected mice have 10-fold less cytotoxicity than wild-type NK cells

liver/biliary system phenotype

liver hemorrhage
- MHV-infected mice develop an acute hemorrhagic liver disease with massive hepatocyte necrosis

mammalian phenotype

immune system phenotype
- Normal - mice infected with the Urbani strain of severe acute respiratory syndrome coronavirus (SARS-CoV) or a recombinant isogenic mouse-adapted SARS-CoV (rMA15) that contains six virulence modifying mutations show no increase in susceptibility, pathogenesis, or histological outcomes to infection compared to wild-type controls

mortality/aging

increased susceptibility to Herpesvirales infection induced morbidity/mortality
- MCMV-treated mice exhibit a 800-fold lower LD50 compared with similarly treated wild-type mice

increased susceptibility to viral infection induced morbidity/mortality
- MCMV-treated mice exhibit a 800-fold lower LD50 compared with similarly treated wild-type mice
- mice infected with 5 pfu MHV die within 48 hours while wild-type mice survive

vision/eye phenotype

corneal vascularization
- corneal injection of a plasmid encoding short hairpin RNA targeting the C terminus of the secreted form of Flt1 (pshRNA-sflt1) induces corneal vascularization within 3 days of injection in wild-type and mutant mice

homeostasis/metabolism phenotype

increased circulating alanine transaminase level
- MHV-infected mice show rapidly rising liver enzyme values in serum

immune system phenotype

abnormal cytokine secretion
- upon viral infection, interferon alpha induction is normal initially, but in later phases does not reach wild-type levels

abnormal dendritic cell physiology
- amplification of dendritic signaling is suppressed in mutant dendritic cells stimulated with poly(I:C); RelA activation is suppressed
- Ifn beta stimulation of dendritic cells elicits a significantly lower response in mutant cells than in wild-type
- in mutant dendritic cells, induction of MHC and costimulatory molecules does not occur in response poly(I:C), in contrast to wild-type cells; LPS or CpG-dependent induction of MHC I and costimulatory molecules is also suppressed
- induction of MHC and costimulatory molecules is abolished in dendritic cells upon infection with Newcastle disease virus (NDC)
- maturation of dendritic cells is impaired when stimulated by poly(I:C), LPS or NDV, but migration in T cell zone of spleen is not affected
- stimulatory activity of CD4+ and CD8+ T cells by poly(I:C) is impaired in poly(I:C)-stimulated mutant dendritic cells; stimulatory activity of CD8+ T cells is impaired in the LPS- or CpG-stimulated dendritic cells to a lesser extent than in poly(I:C)-stimulated cells
- ulated cells

abnormal immunoglobulin level
- levels of IgG1a, IgG2a and IgG2b neutralizing antibodies are reduced relative to controls after secondary infection with Ectromelia virus

abnormal inflammatory response
- in mutant dendritic cells, induction of MHC and costimulatory molecules does not occur in response poly(I:C), in contrast to wild-type cells; LPS or CpG-dependent induction of MHC I and costimulatory molecules is also suppressed
- MHC I induction is severely impaired in response to all three stimuli

abnormal NK cell physiology
- NK cells in vivo make much about a fifth less IFN-gamma in response to injections of the TLR9 agonist CpG
- there is 50% less actively proliferating NK cells in the spleen after MCMV infection compared to controls

impaired natural killer cell mediated cytotoxicity
- NK cells from MCMV-infected mice have 10-fold less cytotoxicity than wild-type NK cells

increased susceptibility to Coronaviridae infection
- mice show increased susceptibility to infection with murine hepatitis virus (MHV) A59 (a coronavirus), showing increased viral titers and developing a rapidly lethal acute hemorrhagic liver disease
- plasmacytoid dendritic cells (pDCs) are more susceptible to MHV infection than wild-type pDCs

increased susceptibility to Herpesvirales infection
- mice are 100-fold more susceptible to MCMV viral infection than controls
- mice infected with HSV-2 strain 186 exhibit more severe clinical scores of disease (genital lesions, redness and swelling) compared with wild-type mice

increased susceptibility to Herpesvirales infection induced morbidity/mortality
- MCMV-treated mice exhibit a 800-fold lower LD50 compared with similarly treated wild-type mice

increased susceptibility to Picornaviridae infection
- increased susceptibility of encephalomyocarditis virus induced lethality

increased susceptibility to Poxviridae infection
- 100% mortality by day 6-12 after primary infection infection
- elevated virus titers in all organs tested after primary infection but much improved after secondary infections
- increased susceptibility to Ectromelia virus
- survive secondary infections

increased susceptibility to viral infection
- 100% mortality by day 6-12 after primary infection infection
- elevated virus titers in all organs tested after primary infection but much improved after secondary infections
- increased susceptibility of encephalomyocarditis virus induced lethality
- increased susceptibility to Ectromelia virus
- mice are 100-fold more susceptible to MCMV viral infection than controls
- mice infected with HSV-2 strain 186 exhibit more severe clinical scores of disease (genital lesions, redness and swelling) compared with wild-type mice
- mice show increased susceptibility to infection with murine hepatitis virus (MHV) A59 (a coronavirus), showing increased viral titers and developing a rapidly lethal acute hemorrhagic liver disease
- plasmacytoid dendritic cells (pDCs) are more susceptible to MHV infection than wild-type pDCs
- survive secondary infections

increased susceptibility to viral infection induced morbidity/mortality
- MCMV-treated mice exhibit a 800-fold lower LD50 compared with similarly treated wild-type mice
- mice infected with 5 pfu MHV die within 48 hours while wild-type mice survive

Genotype: Ifnar1^tm1Agt/Ifnar1^tm1Agt
involves: 129S2/SvPas * C57BL/6

immune system phenotype

altered susceptibility to infection
- infection with hvPR8 produces high titers of 5x10⁷
- infection with lvPR8 produces low titers of 5x10⁴

mammalian phenotype

immune system phenotype
- Normal - mice do not develop chronic polyarthritis

Genotype: Ifnar1^tm1Agt/Ifnar1^tm1Agt
involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL

immune system phenotype

increased susceptibility to Orthomyxoviridae infection
- mice infected with Thogoto virus all succumb within 3 days compared to 5 days for littermate controls

increased susceptibility to viral infection
- mice infected with Thogoto virus all succumb within 3 days compared to 5 days for littermate controls

Genotype: Ifnar1^tm1Agt/Ifnar1^tm1Agt
involves: 129S2/SvPas * 129S6/SvEvTac

hematopoietic system phenotype

abnormal CD8-positive, alpha-beta T cell physiology
- the antigen specificity of CD8 T cells to common LCMV-derived peptides differs from controls with a higher percentage being specific for the GP33-41 peptide

homeostasis/metabolism phenotype

increased circulating interleukin-12 level
- 3-4 pg/ml of IL-12 heterodimer are present in the serum 1.5- and 3- days after infection with LCMV while no IL-12 is detected at this timepoint in wild-type mice

immune system phenotype

abnormal CD8-positive, alpha-beta T cell physiology
- the antigen specificity of CD8 T cells to common LCMV-derived peptides differs from controls with a higher percentage being specific for the GP33-41 peptide

abnormal interferon-gamma secretion
- splenic leukocyte production of IFN-gamma is increased 3-fold 8 days after infection with LCMV compared to controls
- these T cells produce less IFN-gamma on a per cell basis
- two-thirds of this IFN-gamma production is dependent on CD8 T cells

increased circulating interleukin-12 level
- 3-4 pg/ml of IL-12 heterodimer are present in the serum 1.5- and 3- days after infection with LCMV while no IL-12 is detected at this timepoint in wild-type mice

increased susceptibility to Riboviria infection
- mice have a 2-log higher viral titer in the spleen, and a 4-log higher viral titer in the liver, 4.5 days after infection with LCMV virus
- mice took much longer to clear virus, around 28 days, compared to 7 days for wild-type mice

increased susceptibility to viral infection
- mice have a 2-log higher viral titer in the spleen, and a 4-log higher viral titer in the liver, 4.5 days after infection with LCMV virus
- mice took much longer to clear virus, around 28 days, compared to 7 days for wild-type mice

The following phenotype relates to a compound genotype created using this strain

Genotype: Ifnar1^tm1Agt/Ifnar1^tm1Agt
B6.129S2-Ifnar1

hematopoietic system phenotype

abnormal osteoclast morphology
- osteoclastogenesis is enhanced

impaired natural killer cell mediated cytotoxicity
- natural killer cells from polyI:C-treated mice do not display cytotoxicity towards B16 melanoma cells

mortality/aging

increased susceptibility to bacterial infection induced morbidity/mortality
- all mice treated with LPS die unlike control mice

neoplasm

increased tumor growth/size
- in mice treated with polyI:C the reduction in tumor growth of injected B16 melanoma cells is less than in polyI:C treated control mice

skeleton phenotype

abnormal osteoclast morphology
- osteoclastogenesis is enhanced

decreased bone mineral density

immune system phenotype

abnormal osteoclast morphology
- osteoclastogenesis is enhanced

abnormal response to infection
- murine cytomegalovirus replication in macrophages is increased greater than 10,000-fold compared to that in wild-type macrophages

decreased interferon-alpha secretion
- following infection with Leishmania

decreased interferon-beta secretion
- following infection with Leishmania

decreased interleukin-6 secretion
- from bone marrow-derived macrophage stimulated with LPS or E. coli K1 E-R8

decreased tumor necrosis factor secretion
- from bone marrow-derived macrophage stimulated with LPS or E. coli K1 E-R8

impaired natural killer cell mediated cytotoxicity
- natural killer cells from polyI:C-treated mice do not display cytotoxicity towards B16 melanoma cells

increased susceptibility to bacterial infection induced morbidity/mortality
- all mice treated with LPS die unlike control mice

References

Muller U; Steinhoff U; Reis LF; Hemmi S; Pavlovic J; Zinkernagel RM; Aguet M. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264(5167):1918-21PubMed: 8009221 MGI: J:36115

Additional References

Rossi SL; Tesh RB; Azar SR; Muruato AE; Hanley KA; Auguste AJ; Langsjoen RM; Paessler S; Vasilakis N; Weaver SC. 2016. Characterization of a Novel Murine Model to Study Zika Virus. Am J Trop Med Hyg 94(6):1362-9PubMed: 27022155 MGI: J:230104

Additional - Ifnar1^tm1Agt related

Technical Support

CONTACT TECHNICAL SUPPORT

Genotyping Protocols
- Standard PCR:Ifnar1
- Standard PCR:Ifnar1
- Probe:Ifnar1 Probe
- Genotyping resources and troubleshooting
Dietary Information
- LabDiet® 5K52 formulation (6% fat)
Breeding Considerations

When maintaining a live colony, these mice can be bred as homozygotes. SPF conditions are recommended.
- Additional Breeding and Husbandry Support
Mating System
- Homozygote x Homozygote
Citation
When using the IFN-αβR- mouse strain in a publication, please cite the originating article(s) and include MMRRC stock #32045 in your Materials and Methods section.

Animal Health Reports

Facility Barrier Level Descriptions

AX10 (Standard)

Terms Of Use

General Terms and Conditions

See MMRRC for Additional Conditions of Distribution

Questions about Terms of Use

Additional Use Restrictions Apply

Notice regarding distribution of this strain.

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

Credit for PRODUCTS or SERVICES

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Animal Care and Use for SERVICES

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Also Known As:IFN-αβR-

Donating Investigator

Genetic overview

Research Applications

Detailed Description

Development

Control Suggestions

Additional Information

Selected References

Ifnar1tm1Agt

Allele Symbol: Ifnar1tm1Agt

Disease Terms

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Mammalian Phenotype Terms by Genotype

Genotype: Ifnar1tm1Agt/Ifnar1tm1Agtinvolves: 129S2/SvPas

cardiovascular system phenotype

hematopoietic system phenotype

liver/biliary system phenotype

mammalian phenotype

mortality/aging

vision/eye phenotype

homeostasis/metabolism phenotype

immune system phenotype

Genotype: Ifnar1tm1Agt/Ifnar1tm1Agtinvolves: 129S2/SvPas * C57BL/6

immune system phenotype

mammalian phenotype

Genotype: Ifnar1tm1Agt/Ifnar1tm1Agtinvolves: 129S2/SvPas * BALB/c * C57BL/6 * SJL

immune system phenotype

Genotype: Ifnar1tm1Agt/Ifnar1tm1Agtinvolves: 129S2/SvPas * 129S6/SvEvTac

hematopoietic system phenotype

homeostasis/metabolism phenotype

immune system phenotype

Genotype: Ifnar1tm1Agt/Ifnar1tm1AgtB6.129S2-Ifnar1

hematopoietic system phenotype

mortality/aging

neoplasm

skeleton phenotype

immune system phenotype

References

Additional References

Additional - Ifnar1tm1Agt related

Genotyping Protocols

Dietary Information

Breeding Considerations

Mating System

Citation

Animal Health Reports

The Jackson Laboratory's Genotype Promise

Terms Of Use

Additional Use Restrictions Apply

Licensing Information

JAX® Mice, Products & Services Conditions of Use

No Warranty

Credit for PRODUCTS or SERVICES

Animal Care and Use for SERVICES

No Liability

Ifnar1^tm1Agt

Allele Symbol: Ifnar1^tm1Agt

Genotype: Ifnar1^tm1Agt/Ifnar1^tm1Agt
involves: 129S2/SvPas

Genotype: Ifnar1^tm1Agt/Ifnar1^tm1Agt
involves: 129S2/SvPas * C57BL/6

Genotype: Ifnar1^tm1Agt/Ifnar1^tm1Agt
involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL

Genotype: Ifnar1^tm1Agt/Ifnar1^tm1Agt
involves: 129S2/SvPas * 129S6/SvEvTac

Genotype: Ifnar1^tm1Agt/Ifnar1^tm1Agt
B6.129S2-Ifnar1

Additional - Ifnar1^tm1Agt related